Charles River Laboratories International Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Charles River Laboratories International Inc 公司

Charles River Laboratories International, Inc. 提供基本产品和服务，帮助全球制药和生物技术公司、政府机构和学术机构加速其研究和药物开发工作。该公司的研究模型和服务部门由三项业务组成，提供基础工具，使其客户能够发现新分子：研究模型、研究模型服务和细胞解决方案。其发现和安全评估部门提供受监管和非受监管的 DSA 服务，以支持潜在新药的研究、开发和监管要求的安全测试，包括治疗发现和优化以及体外和体内研究、实验室支持服务以及战略非临床咨询和项目管理，以支持产品开发。其制造解决方案部门包括微生物解决方案和生物制剂解决方案。

公司简介

公司代码CRL

公司名称Charles River Laboratories International Inc

上市日期Jun 23, 2000

成立日期1994

CEOMr James C. Foster

员工数量18600

证券类型Ordinary Share

年结日Jun 23

公司地址251 Ballardvale St

城市WILMINGTON

上市交易所NYSE Consolidated

国家United States of America

邮编01887

电话17812226000

网址https://www.criver.com/

公司代码CRL

上市日期Jun 23, 2000

成立日期1994

公司高管

名称

名称/职务

职务

持股

持股变动

Mr James C. Foster

Chairman of the Board, President, Chief Executive Officer

250.71K

+1.11%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

46.41K

-3.11%

Mr. Robert J. (Bob) Bertolini, CPA

Independent Director

32.80K

--

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

12.03K

-27.10%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

8.38K

-4.21%

Dr. Deborah Turner Kochevar, Ph.D.

Independent Director

7.89K

--

Ms. Shannon M. Parisotto

Corporate Executive Vice President - Discovery and Safety Assessment Management

7.60K

+20.39%

Mr. George E. Massaro, CPA

Independent Director

5.86K

--

Ms. Virginia M. (Gina) Wilson, CPA

Independent Director

3.96K

--

Dr. Nancy C. Andrews, M.D., Ph.D.

Independent Director

3.02K

--

名称

名称/职务

职务

持股

持股变动

Mr James C. Foster

Chairman of the Board, President, Chief Executive Officer

250.71K

+1.11%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

46.41K

-3.11%

Mr. Robert J. (Bob) Bertolini, CPA

Independent Director

32.80K

--

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

12.03K

-27.10%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

8.38K

-4.21%

Dr. Deborah Turner Kochevar, Ph.D.

Independent Director

7.89K

--

收入明细

单位: USD更新时间: 4月6日周日

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

业务USD

名称

营收

占比

DSA

2.45B

60.53%

RMS

829.38M

20.48%

Manufacturing

769.33M

19.00%

地区USD

名称

营收

占比

United States

2.24B

55.31%

Europe

1.08B

26.62%

Canada

482.09M

11.90%

Asia Pacific (Region)

196.95M

4.86%

Other

52.82M

1.30%

业务

地区

业务USD

名称

营收

占比

DSA

2.45B

60.53%

RMS

829.38M

20.48%

Manufacturing

769.33M

19.00%

股东统计

更新时间: 2月21日周五

持股股东

股东类型

持股股东

股东统计

占比

The Vanguard Group, Inc.

12.49%

Wellington Management Company, LLP

8.30%

BlackRock Institutional Trust Company, N.A.

6.01%

State Street Global Advisors (US)

4.44%

Kayne Anderson Rudnick Investment Management, LLC

3.68%

Other

65.09%

持股股东

股东统计

占比

The Vanguard Group, Inc.

12.49%

Wellington Management Company, LLP

8.30%

BlackRock Institutional Trust Company, N.A.

6.01%

State Street Global Advisors (US)

4.44%

Kayne Anderson Rudnick Investment Management, LLC

3.68%

Other

65.09%

股东类型

股东统计

占比

Investment Advisor/Hedge Fund

51.79%

Investment Advisor

38.24%

Hedge Fund

12.50%

Research Firm

4.86%

Pension Fund

1.55%

Bank and Trust

1.37%

Sovereign Wealth Fund

1.16%

Individual Investor

0.91%

Insurance Company

0.07%

机构持股

更新时间: 1月20日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q1

1384

55.02M

112.00%

-3.67M

2024Q4

1423

54.85M

107.26%

-4.35M

2024Q3

1392

53.78M

105.14%

-5.12M

2024Q2

1399

54.00M

104.84%

-4.00M

2024Q1

1393

53.76M

104.37%

-4.04M

2023Q4

1424

53.56M

104.42%

-4.24M

2023Q3

1446

53.56M

104.42%

-3.98M

2023Q2

1427

52.88M

103.32%

-3.95M

2023Q1

1431

52.72M

103.01%

-2.79M

2022Q4

1416

51.28M

100.65%

-3.46M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

6.13M

12.49%

+58.13K

+0.96%

Dec 31, 2024

Wellington Management Company, LLP

4.08M

8.3%

+335.66K

+8.97%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

2.95M

6.01%

-51.78K

-1.72%

Dec 31, 2024

State Street Global Advisors (US)

2.18M

4.44%

+51.15K

+2.40%

Dec 31, 2024

Kayne Anderson Rudnick Investment Management, LLC

1.81M

3.68%

-134.28K

-6.92%

Dec 31, 2024

Allspring Global Investments, LLC

1.81M

3.68%

+47.22K

+2.68%

Dec 31, 2024

Geode Capital Management, L.L.C.

1.23M

2.51%

+14.79K

+1.21%

Dec 31, 2024

Impactive Capital LP

1.20M

2.45%

+825.95K

+219.44%

Dec 31, 2024

Meritage Group LP

1.07M

2.19%

-111.05K

-9.37%

Dec 31, 2024

Ariel Investments, LLC

1.07M

2.17%

+169.64K

+18.90%

Dec 31, 2024

持股ETF

更新时间: 4月6日周日

机构名称

占比

First Trust NASDAQ Pharmaceuticals ETF

2.3%

Janus Henderson Small/Mid Cap Growth Alpha ETF

2.1%

Schwab Ariel ESG ETF

1.64%

First Trust Health Care Alphadex Fund

1.55%

VanEck Biotech ETF

1.44%

Invesco S&P 500 Equal Weight Health Care ETF

1.35%

ROBO Global Healthcare Technology & Innovation ETF

1.34%

Franklin Genomic Advancements ETF

1.25%

Hilton Small-MidCap Opportunity ETF

1.07%

Amplify AI Powered Equity ETF

1.02%

First Trust NASDAQ Pharmaceuticals ETF

占比2.3%

Janus Henderson Small/Mid Cap Growth Alpha ETF

占比2.1%

Schwab Ariel ESG ETF

占比1.64%

First Trust Health Care Alphadex Fund

占比1.55%

VanEck Biotech ETF

占比1.44%

Invesco S&P 500 Equal Weight Health Care ETF

占比1.35%

ROBO Global Healthcare Technology & Innovation ETF

占比1.34%

Franklin Genomic Advancements ETF

占比1.25%

Hilton Small-MidCap Opportunity ETF

占比1.07%

Amplify AI Powered Equity ETF

占比1.02%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Charles River Laboratories International Inc

115.555USD

Charles River Laboratories International Inc

115.555

概览

公司